XW013S9Introduction of Epcoritamab Monoclonal Antibody into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 9

New Technology›Anatomical Regions›Introduction
  • Billable / Specific Code
ICD-10-PCS XW013S9
CMS Source: FY 2027 ICD-10-PCS dataset. Effective Oct 1, 2026 – Sep 30, 2027.FacebookXLinkedInPrint

XW013S9 is a billable ICD-10-PCS procedure code for Introduction of Epcoritamab Monoclonal Antibody into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 9. It is valid on HIPAA claims for fiscal year 2027 (October 1, 2026 through September 30, 2027). The root operation Introduction involves putting in or on a therapeutic, diagnostic, nutritional, physiological, or prophylactic substance except blood or blood products. The Alphabetic Index lists this code under Epcoritamab Monoclonal Antibody. In AHRQ's Clinical Classifications Software (CCSR), this procedure falls under Chemotherapy.

Code Identity

ICD-10-PCS Code
XW013S9
Billable Status
Yes — Valid for Submission
Code Describes
Introduction of Epcoritamab Monoclonal Antibody into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 9
Short Description
Introduce Epcoritamab Moncln Ab in Subcu, Perc, New Tech 9
Parent Code
XW0

PCS Table Breakdown

Each ICD-10-PCS code is built from seven characters, each an axis of the procedure. Hover or tap the icons for the official CMS definitions.

PositionDesignationValueMeaning
1SectionXNew Technology
2Body SystemWAnatomical Regions
3Operation0Introduction
4BodyPart1Subcutaneous Tissue
5Approach3Percutaneous
6Device/Substance/TechnologySEpcoritamab Monoclonal Antibody
7Qualifier9New Technology Group 9

In the ICD-10-PCS Alphabetic Index

The FY 2027 ICD-10-PCS Alphabetic Index refers to XW013S9 as Epcoritamab Monoclonal Antibody. These index entries lead to this code:

Epcoritamab Monoclonal Antibody
Direct entry for this code
New Technology, Epcoritamab Monoclonal Antibody
Direct entry for this code
EPKINLY(tm)
Anatomy or device term that leads here
Iloprost
Leads to this code's table
Sarilumab
Leads to this code's table
Posoleucel
Leads to this code's table
Rezafungin
Leads to this code's table
Treosulfan
Leads to this code's table
Baricitinib
Leads to this code's table
Sabizabulin
Leads to this code's table
Tocilizumab
Leads to this code's table
Caplacizumab
Leads to this code's table
COVID-19 Vaccine
Leads to this code's table
Inebilizumab-cdon
Leads to this code's table
Sulbactam-Durlobactam
Leads to this code's table

To code epcoritamab monoclonal antibody, open the FY 2027 ICD-10-PCS Alphabetic Index at Epcoritamab Monoclonal Antibody. The entry lists XW013S9 directly as a complete, billable code.

Browse the full ICD-10-PCS Alphabetic Index →

Clinical Classification (CCSR)

AHRQ groups this procedure code into these clinical categories.

ADM012
Chemotherapy
Clinical domain: Administration of Therapeutic Substances

Code History

Replaces previously assigned code(s):
  • 3E0130M — Introduction of Antneo, Moncln Ab, into Subcu, Perc Approach

Similar Procedure Codes

Questions About XW013S9

Is XW013S9 a billable code?

Yes. This is a complete seven-character ICD-10-PCS code, specific enough to report Introduction of Epcoritamab Monoclonal Antibody into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 9 on inpatient claims from October 1, 2026 through September 30, 2027.

What is the ICD-10-PCS code for epcoritamab Monoclonal Antibody?

The ICD-10-PCS Alphabetic Index lists Epcoritamab Monoclonal Antibody under code XW013S9, Introduction of Epcoritamab Monoclonal Antibody into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 9, billable on inpatient claims in fiscal year 2027.

What do the characters in XW013S9 mean?

The code breaks down character by character: the 1st character X is the Section (New Technology); the 2nd character W is the Body System (Anatomical Regions); the 3rd character 0 is the Operation (Introduction); the 4th character 1 is the BodyPart (Subcutaneous Tissue); the 5th character 3 is the Approach (Percutaneous); the 6th character S is the Device/Substance/Technology (Epcoritamab Monoclonal Antibody); the 7th character 9 is the Qualifier (New Technology Group 9).